By Adriano Marchese

AstraZeneca PLC (AZN.LN) said Friday that its drug Roxadustat significantly increased hemoglobin levels for chronic kidney disease patients with anemia in Phase 3 Olympus and Rockies trials.

The drugmaker said the results of the global Phase 3 program as well as other data will form part of a regulatory submission in the U.S., which is anticipated in the fourth quarter of 2019.

Roxadustat is currently approved in China for the treatment of anemia in patients with CKD, regardless of whether they require dialysis, the company said.

Write to Adriano Marchese at adriano.marchese@wsj.com

(END) Dow Jones Newswires

November 08, 2019 02:33 ET (07:33 GMT)

Copyright (c) 2019 Dow Jones & Company, Inc.
Astrazeneca (LSE:AZN)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Astrazeneca Charts.
Astrazeneca (LSE:AZN)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Astrazeneca Charts.